We are independent & ad-supported. We may earn a commission for purchases made through our links.
Advertiser Disclosure
Our website is an independent, advertising-supported platform. We provide our content free of charge to our readers, and to keep it that way, we rely on revenue generated through advertisements and affiliate partnerships. This means that when you click on certain links on our site and make a purchase, we may earn a commission. Learn more.
How We Make Money
We sustain our operations through affiliate commissions and advertising. If you click on an affiliate link and make a purchase, we may receive a commission from the merchant at no additional cost to you. We also display advertisements on our website, which help generate revenue to support our work and keep our content free for readers. Our editorial team operates independently of our advertising and affiliate partnerships to ensure that our content remains unbiased and focused on providing you with the best information and recommendations based on thorough research and honest evaluations. To remain transparent, we’ve provided a list of our current affiliate partners here.
Health

Our Promise to you

Founded in 2002, our company has been a trusted resource for readers seeking informative and engaging content. Our dedication to quality remains unwavering—and will never change. We follow a strict editorial policy, ensuring that our content is authored by highly qualified professionals and edited by subject matter experts. This guarantees that everything we publish is objective, accurate, and trustworthy.

Over the years, we've refined our approach to cover a wide range of topics, providing readers with reliable and practical advice to enhance their knowledge and skills. That's why millions of readers turn to us each year. Join us in celebrating the joy of learning, guided by standards you can trust.

What is a Parp Inhibitor?

Mary McMahon
By
Updated: May 17, 2024
Views: 6,146
Share

A parp or PARP inhibitor is an antineoplastic drug that works by interfering with the DNA repair process in cancerous cells. Drugs in this class can be used alone or with other chemotherapy agents. As of 2011, parp inhibitors were primarily investigational drugs, with researchers studying their potential applications in laboratory and clinical trial environments. This drug class has considerable appeal to cancer researchers and doctors, as it can attack cancers without damaging neighboring cells in the body.

Poly(ADP-ribose) polymerase (PARP) is an enzyme involved in the process of DNA repair. Every time cells multiply and divide, there is a risk of DNA damage, addressed with built-in repair systems. Certain types of tumors rely heavily on the parp enzyme to repair themselves. These tumors can be vulnerable to targeting with agents designed to lock onto the enzyme. A parp inhibitor interferes with this process, killing the cancer cells by making it impossible to repair their DNA. The dead cells cannot replicate and the tumor will stop growing and eventually start shrinking as cells die off.

When used alone, a parp inhibitor can attack a cancer without damaging cells near the cancer, as it does not target healthy cells, only cancer cells relying on parp for DNA repair. It can also be used with another chemotherapeutic agent, mopping up after the other drug to kill cancer cells the first drug is unable to reach. Combination therapy can be highly effective in cancer treatment by attacking a cancer from multiple angles.

A parp inhibitor is not effective on all types of cancers. Cancer cells are highly diverse and some do not rely heavily on this enzyme for DNA repair, making them unsuitable targets for drugs in this class. Research on these drugs has shown them to be effective for treatment of some breast cancers, including breast cancers without susceptibility to other common drug targets, like human epidermal growth factor receptor 2 (HER-2).

Preliminary studies on parp inhibitor drugs showed promise, leading researchers to express excitement about the potential applications of these medications. The lack of cytotoxicity to healthy cells is a particularly important trait for cancer medications. Many chemotherapy regimens are grueling for patients, and can come with considerable complications and side effects. These can potentially endanger patients, as well as making it harder for patients to comply with prescribed treatments. Medications capable of targeting cancer cells only and leaving healthy cells alone represent a new generation of cancer drugs.

Share
WiseGeek is dedicated to providing accurate and trustworthy information. We carefully select reputable sources and employ a rigorous fact-checking process to maintain the highest standards. To learn more about our commitment to accuracy, read our editorial process.
Mary McMahon
By Mary McMahon

Ever since she began contributing to the site several years ago, Mary has embraced the exciting challenge of being a WiseGeek researcher and writer. Mary has a liberal arts degree from Goddard College and spends her free time reading, cooking, and exploring the great outdoors.

Editors' Picks

Discussion Comments
Mary McMahon
Mary McMahon

Ever since she began contributing to the site several years ago, Mary has embraced the exciting challenge of being a...

Learn more
Share
https://www.wisegeek.net/what-is-a-parp-inhibitor.htm
Copy this link
WiseGeek, in your inbox

Our latest articles, guides, and more, delivered daily.

WiseGeek, in your inbox

Our latest articles, guides, and more, delivered daily.